Identifying pathogenic proteins leads to potential new treatments for diseases such as diabetes.

Published Date: 02 Mar 2023

New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.

Read Full News

Latest News

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

HCPLive 5 Stories in Under 5: Week of 01/04

HCPLive 5 Stories in Under 5: Week of 01/04

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Latest News

HCPLive 5 Stories in Under 5: Week of 01/11

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

HCPLive 5 Stories in Under 5: Week of 01/04

FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D

The HCPFive: Top News for Healthcare Providers from the Week of 01/04

News All Time

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Gestational Diabetes Linked to Reduced Lung Function in Children

Gestational Diabetes Linked to Reduced Lung Function in Children

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

5 Endocrinology Headlines You Missed in November 2025

5 Endocrinology Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management

Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management

Evidence builds for disrupted mitochondria as cause of Parkinson's

For decades, scientists have known that mitochondria, which produce energy inside our cells, malfunction in Parkinson's disease. But a critical question remained: do the failing mitochondria cause Parkinson's, or do they ...

Keto diet associated with reduced depressive symptoms, anxiety results remain mixed

Researchers led by St Michael's Hospital in Toronto report that ketogenic diets are associated with modest reductions in depressive symptoms in adults, while evidence for anxiety remains uncertain.

Some women start menopause after surgery or medical treatment: Here's how it's different

For most women, menopause occurs naturally around the age of 49. In the lead up to menopause, the quality and quantity of eggs declines over time. Then the ovaries stop releasing eggs completely.

How painkillers can contribute to anemia in cancer patients

Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the iron metabolism of liver cancer cells and can thus contribute to iron deficiency and anemia in cancer ...

Study reveals how uterine contractions are regulated by stretch and pressure during childbirth

When labor begins, the uterus must coordinate rhythmic, well-timed contractions to deliver the baby safely. While hormones such as progesterone and oxytocin are key contributors to that process, scientists have long suspected ...

Recommended News For You

New research points out a promising strategy for treating metastatic medulloblastoma

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

Medicaid expansion tied to smaller declines in early-stage cancer detection

Recommended Articles For You

Unlocking the Potential of Cancer Antigen 19-9 for Early Detection 

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer 

Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology 

Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Hereditary cancer has a rare and underreported cause.

2.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

3.

Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality

4.

Exercise can counter detrimental effects of cancer treatment, review suggests

5.

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement

1.

Interpreting Iron Studies: What Your Blood Results Really Mean 

2.

Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life

3.

Decoding the Future: Cancer Genomics and Radiomics in Oncology

4.

The Importance of Having a Quick and Effective Heparin Antidote 

5.

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

3.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot